An automated methodology for levodopa-induced dyskinesia: Assessment based on gyroscope and accelerometer signals

Artificial Intelligence in Medicine

Volumn 55, Issue 2, 2012, Pages 127-135

  Tsipouras, Markos G ^a   Tzallas, Alexandros T ^a   Rigas, George ^a   Tsouli, Sofia ^b   Fotiadis, Dimitrios I ^a   Konitsiotis, Spiros ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Accelerometers; Classification; Gyroscopes; Levodopa induced dyskinesia assessment; Parkinson's disease; Wearable devices

Indexed keywords

ACCELEROMETER SIGNALS; ANALYSIS OF SIGNAL; CLASSIFICATION TECHNIQUE; CROSS VALIDATION; CROSS-VALIDATION TECHNIQUE; LEVODOPA-INDUCED DYSKINESIA ASSESSMENT; MOTOR TASKS; PARKINSON'S DISEASE; POSITIVE PREDICTIVE VALUES; VOLUNTARY MOVEMENT; WEARABLE DEVICES;

ACCELEROMETERS; CLASSIFICATION (OF INFORMATION); GYROSCOPES; NEURODEGENERATIVE DISEASES;

RATING;

LEVODOPA;

ACCELEROMETER; ADULT; AGED; ARTICLE; AUTOMATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DYSKINESIA; GYROSCOPE; HUMAN; LEVODOPA INDUCED DYSKINESIA; METHODOLOGY; MOTOR PERFORMANCE; NEUROLOGIST; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; VOLUNTARY MOVEMENT;

AGED; AUTOMATION; BIOSENSING TECHNIQUES; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MIDDLE AGED; MONITORING, AMBULATORY; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84861526299     PISSN: 09333657     EISSN: 18732860     Source Type: Journal    
DOI: 10.1016/j.artmed.2012.03.003     Document Type: Article

References (29)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis, Journal of Neurology. Neurosurgery & Psychiatry 2008, 79:368-376.
2. Dorsey E.R., Constantinescu R., Thompson J.R., Biglan K.M., Holloway R.G., Kieburtz K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
3. The Parkinson Study Group Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine 2004, 351:2498-2508.
4. Keijsers N.L., Horstink M.W., Gielen S.C. Online monitoring of dyskinesia in patients with Parkinson's disease. IEEE Engineering in Medicine and Biology Magazine 2003, 22:96-103.
5. Hoff J.I., van Hilten J.J., Roos R.A. A review of the assessment of dyskinesias. Movement Disorders 2001, 16:737-743.
6. Yanagisawa N. EMG characteristics of involuntary movements. Dyskinesias 1984, 142-159. Sandoz BV, Uden. G.W. Bruyn (Ed.).
7. Haines J., Sainsbury P. Ultrasound system for measuring patients' activity and disorders of movement. Lancet 1972, 14:802-803.
8. Burkhard P.R., Shale H., Langston L.W., Tetrud J.W. Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method. Movement Disorders 1999, 14:754-763.
9. Keijsers N.L., Horstink M.W., van Hilten J.J., Hoff J.I., Gielen S.C. Detection and assessment of the severity of Levodopa-induced dyskinesia in patients with Parkinson's Disease by neural networks. Movement Disorders 2000, 15:1104-1111.
10. Hoff J.I., van den Plas A.A., Wagemans E.A., van Hilten J.J. Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease. Movement Disorders 2001, 16:58-61.
11. Keijsers N.L., Horstink M.W., Gielen S.C. Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks. Movement Disorders 2003, 18:70-80.
12. Patel S., Lorincz K., Hughes R., Huggins N., Growdon J., Standaert D., et al. Monitoring motor fluctuations in patients with Parkinson's disease using wearable sensors. IEEE Transactions on Information Technology in Biomedicine 2009, 13:864-873.
13. Ghassemi M., Lemieux S., Jog M., Edwards R., Duval C. Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias. Brain Research Bulletin 2006, 69:512-518.
14. Gourb J., Edwards R., Lemieux S., Ghassemi M., Jog M., Duval C. Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease. Brain Research Bulletin 2007, 74:66-74.
15. Chelaru M.I., Duval C., Jog M. Levodopa-induced dyskinesias detection based on the complexity of involuntary movements. Journal of Neuroscience Methods 2010, 186:81-89.
16. Liu X., Carroll C.B., Wang S.Y., Zajicek J., Bain P.G. Quantifying drug-induced dyskinesias in the arms using digitized spiral-drawing tasks. Journal of Neuroscience Methods 2005, 144:47-52.
17. ANCO. Available from: . http://www.anco.gr/.
18. Fahn S., Elton R. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1986, 153-164. Macmillan Health Care Information, Florham Park, NJ. S. Fahn, C. Marsden, D. Calne (Eds.).
19. Kaburlasos V.G., Athanasiadis I.N., Mitkas P.A. Fuzzy lattice reasoning (FLR) classifier and its application for ambient ozone estimation. International Journal of Approximate Reasoning 2007, 45:152-188.
20. Quinlan J.R. C4.5 1993, Morgan Kauffman, San Mateo.
21. Breiman L. Random forests. Machine Learning 2001, 45:5-32.
22. Witten I.H., Frank E. Data mining: practical machine learning tools and techniques 2005, Morgan Kaufmann, CA, USA.
23. Tan P.N., Steinbach M., Kumar V. Introduction to data mining 2005, Addison-Wesley Longman Publishing, MA, USA.
24. Knight J.F., Baber C.A. A tool to assess the comfort of wearable computers. Human Factors 2005, 47:77-91.
25. Hauser R.A., Rascol O., Korczyn A.D., Jon Stoessl A., Watts R.L., Poewe W., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders 2007, 22:2409-2417.
26. Fabbrini G., Mouradian M.M., Junecos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part I. Annals of Neurology 1988, 22:366-371.
27. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders 2001, 16:448-458.
28. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and clinical implications. The Lancet Neurology 2006, 5:677-687.
29. Péchevis M., Clarke C.E., Vieregge P., Khoshnood B., Deschaseaux-Voinet C., Berdeaux G., et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. European Journal of Neurology 2005, 12:956-963.